The potential impact of routine immunization with inactivated poliovirus vaccine onwild-type or vaccine-derived poliovirus outbreaks in a posteradication setting

American Journal of Epidemiology

Volumn 178, Issue 10, 2013, Pages 1579-1587

  Mangal, Tara D ^a   Aylward, R Bruce ^b   Grassly, Nicholas C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Disease transmission; Inactivated poliovirus vaccine; Oral poliovirus vaccine; Poliomyelitis; Poliovirus eradication

Indexed keywords

NEUTRALIZING ANTIBODY; POLIOMYELITIS VACCINE;

DISEASE SPREAD; DISEASE TRANSMISSION; HEALTH RISK; IMMUNIZATION; POLIOMYELITIS; VACCINE;

ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; EPIDEMIC; HISTORY; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; MATHEMATICAL MODEL; POLIOMYELITIS; POLIOMYELITIS VIRUS; PREVALENCE; SENSITIVITY ANALYSIS; SEROCONVERSION; STOCHASTIC MODEL; SUSCEPTIBLE POPULATION; VACCINATION; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS SHEDDING; VIRUS TRANSMISSION;

DISEASE TRANSMISSION; INACTIVATED POLIOVIRUS VACCINE; ORAL POLIOVIRUS VACCINE; POLIOMYELITIS; POLIOVIRUS ERADICATION;

DISEASE OUTBREAKS; HUMANS; IMMUNIZATION; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL;

POLIOVIRUS;

EID: 84890024036     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt203     Document Type: Article

References (63)

1. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14(2):568-579.
2. Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362(25):2360-2369.
3. Wringe A, Fine PEM, Sutter RW, et al. Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE. 2008; 3(10):e3433.
4. Global Polio Eradication Initiative. Circulating Vaccinederived Poliovirus (cVDPV) 2000-2012. Geneva, Switzerland: Global Polio Eradication Initiative; 2012. (http://www. polioeradication.org/DataandMonitoring/ PolioThisWeek/CirculatingVaccineDerivedPoliovirus.aspx). (Accessed August 28, 2012).
5. Centers for Disease Control and Prevention. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep. 2009;58(30):829-830.
6. Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. In: Plotkin SA, OrensteinWA, eds. Vaccines. Philadelphia, PA: WB Saunders Company; 2008:605-629.
7. Ogra PL, Karzon DT, Righthand F, et al. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med. 1968;279(17):893-900.
8. Wehrle PF, Reichert R, Carbonaro O, et al. Influence of prior active immunization on the presence of poliomyelitis virus in the pharynx and stools of family contacts of patients with paralytic poliomyelitis. Pediatrics. 1958;21(3):353-361.
9. Gelfand HM, LeBlanc DR, Potash L, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg. 1959;70(3):312-327.
10. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599.
11. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec. 2010;85(23):213-228.
12. Strategic Advisory Group of Experts,World Health Organization. IPV Recommended for Countries to Mitigate Risks and Consequences Associated With OPV2 Withdrawal. Geneva, Switzerland:World Health Organization; 2012. (http://www.who.int/immunization/sage/meetings/2012/november/ news-sage-ipv-opv-nov2012/en/index.html). (Accessed November 22, 2012).
13. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012 - conclusions and recommendations. Wkly Epidemiol Rec. 2012;87(21): 201-216.
14. Salk J. One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. Rev Infect Dis. 1984;6(suppl 2): S444-S450.
15. Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201(9):1344-1352.
16. Estivariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: A community-based, randomised controlled trial. Lancet Infect Dis. 2012; 12(2):128-135.
17. Cadorna-Carlos J, Vidor E, Bonnet M-C. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012;16(2):e110-e116.
18. Taranger J, Trollfors B, Knutsson N, et al. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine. 1999;18(9-10):884- 891.
19. Carlsson RM, Claesson BA, Fagerlund E, et al. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J. 2002;21(6):535-541.
20. Mallet E, Matisse N, Mathieu N, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: Immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine. 2004;22(11-12): 1415-1422.
21. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: Past and present experience. Vaccine. 1996; 14(8):735-746.
22. Marine WM, Chin TDY, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg. 1962;76(2):173-195.
23. Stickle G. Observed and expected poliomyelitis in the United States, 1958-1961. Am J Public Health 1964;54(8): 1222-1229.
24. Melnick JL, Ledinko N. Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period. Am J Hyg. 1953;58(2): 207-222.
25. Penttinen K, Patiala R. The paralytic/infected ratio in a susceptible population during a polio type I epidemic. Ann Med Exp Biol Fenn. 1961;39:195-202.
26. World Health Organization. Cessation of Routine Oral Poliovirus Vaccine (OPV) Use After Global Polio Eradication. Framework for National Policy Makers in OPV-using Countries. Geneva, Switzerland:World Health Organization; 2005:6-7.
27. Fine PE. Herd immunity: History, theory, practice. Epidemiol Rev. 1993;15(2):265-302.
28. Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587-635.
29. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. Am J Epidemiol. 2005; 162(4):358-372.
30. Prevots DR, Atti ML, Sallabanda A, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: High attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis. 1998;26(2):419-425.
31. Oostvogel PM, Vanwijngaarden JK, Vanderavoort H, et al. Poliomyelitis outbreak in an unvaccination community in the Netherlands, 1992-93. Lancet. 1994;344(8923):665-670.
32. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296(5566):356-359.
33. Conyn-van Spaendonck MAE, Oostvogel PM, van Loon AM, et al. Circulation of poliovirus during the poliomyelitis outbreak in the Netherlands in 1992-1993. Am J Epidemiol. 1996;143(9):929-935.
34. Henry JL, Jaikaran ES, Davies JR, et al. A study of poliovaccination in infancy: Excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond). 1966;64(1):105-120.
35. Ghendon YZ, Sanakoyeva I. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virol. 1961;5:265-273.
36. Galindo M, Lago P, Caceres V, et al. Randomized, placebocontrolled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med. 2007;365(15):1536-1544.
37. Laassri M, Lottenbach K, Belshe R, et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis. 2005;192(12):2092-2098.
38. Enders-Ruckle G, Siegert R. Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle). Dtsch Med Wochenschr. 1961;86:1999-2008.
39. Sutter RW, Patriarca PA. Inactivated and live, attenuated poliovirus vaccines: Mucosal immunity. In: Kurstak E, ed. Measles and Poliomyelitis. New York, NY: Springer-Verlag New York; 1993.
40. Rezapkin G, Neverov A, Cherkasova E, et al. Repertoire of antibodies against type 1 poliovirus in human sera. J Virol Methods. 2010;169(2):322-331.
41. Onorato IM, Modlin JF, McBean AM, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis. 1991;163(1):1-6.
42. Alexander JP, Gary HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: A review of the literature. J Infect Dis. 1997; 175(suppl 1):S176-S182.
43. Grassly NC, Jafari H, Bahl S, et al. Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination. J Infect Dis. 2010;201(10): 1535-1543.
44. Okayasu H, Sutter RW, Czerkinsky C, et al. Mucosal immunity and poliovirus vaccines: Impact on wild poliovirus infection and transmission. Vaccine. 2011; 29(46):8205-8214.
45. Herremans TM, Reimerink JH, Buisman AM, et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999;162(8):5011-5018.
46. VanWijngaarden JK, Van Loon AM. The polio epidemic in the Netherlands, 1992/1993. Public Health Rev. 1993-1994; 21(1-2):107-116.
47. Layng J, Crapnell V, Palmer G, et al. Paralytic poliomyelitis in contacts of Netherlands travelers - Alberta and British Columbia. Can Dis Wkly Rep. 1978;4:31.
48. Bijkerk H. Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand. 1979;43:195-206.
49. Rümke HC, Schlumberger M, Floury B, et al. Serological evaluation of a simplified immunization schedule using quadruple DPT-polio vaccine in Burkina Faso. Vaccine. 1993;11(11):1113-1118.
50. Simoes EAF, John TJ. The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. J Biol Stand. 1986;14(2):127-131.
51. Slater PE, Costin C, Yarrow A, et al. Poliomyelitis outbreak in Israel in 1988: A report with two commentaries. Lancet. 1990;335(8699):1192-1195.
52. World Health Organization. Global and Regional Immunization Profile: African Region. Geneva, Switzerland: World Health Organization; 2012. (http://apps.who.int/immunization-monitoring/en/globalsummary/GS-AFRProfile.pdf) . (Accessed April 30, 2013).
53. World Health Organization. Global and Regional Immunization Profile: European Region. Geneva, Switzerland: World Health Organization; 2012. (http://apps.who.int/immunization-monitoring/en/globalsummary/GS-EURProfile.pdf) . (Accessed April 30, 2013).
54. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis. 1997; 175(suppl 1):S165-S172.
55. Bill & Melinda Gates Foundation. Water, Sanitation & Hygiene: Strategy Overview. Seattle,WA: Bill & Melinda Gates Foundation; 2013. (http://www.gatesfoundation.org/What-We-Do/Global-Development/ Water-Sanitation-and-Hygiene). (Accessed April 30, 2013).
56. Grassly NC, Fraser C,Wenger J, et al. New strategies for the elimination of polio from India. Science. 2006;314(5802): 1150-1153.
57. Krugman S,Warren J, Eiger MS, et al. Immunization with live attenuated poliovirus vaccine. Am J Dis Child. 1961;101(1): 23-29.
58. Casey AE. The incubation period in epidemic poliomyelitis. J Am Med Assoc. 1942;120(11):805-807.
59. Gelfand HM, LeBlanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana II. Description and analysis of episodes of infection observed in study households. Am J Hyg. 1957; 65(3):367-385.
60. Hatch LA, Hughes KE, Pilfold JN. Observations on the excretion of type 1 poliovirus from cases and their contacts. Am J Med Sci. 1958;236(4):419-424.
61. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine (live). In: Plotkin SA, OrensteinWA, Offit PA, eds. Vaccines. Philadelphia, PA: WB Saunders Company; 2008:631-686.
62. Nathanson N, Martin Jr. The epidemiology of poliomyelitis: Enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol. 1979;110(6):672-692.
63. Fine PE, Sutter RW, OrensteinWA. Stopping a polio outbreak in the post-eradication era. Dev Biol (Basel). 2001;105:129-147.